<person-group /><source>Biochemie and Pathobiochemie</source><issue>7th</issue><publisher>Springer</publisher><other>Berlin, Heidelberg, New York</other><year>2003</year>
<author><surname>Samuelsson</surname><given-names>B.</given-names></author><author><surname>Morgenstern</surname><given-names>R.</given-names></author><author><surname>Jakobsson</surname><given-names>P. J.</given-names></author><title>Membrane prostaglandin E synthase-1: a novel therapeutic target</title><source>Pharmacol. Rev.</source><year>2007</year><volume>59</volume>
<author><surname>Mehrotra</surname><given-names>S.</given-names></author><author><surname>Morimiya</surname><given-names>A.</given-names></author><author><surname>Agarwal</surname><given-names>B.</given-names></author><author><surname>Konger</surname><given-names>R.</given-names></author><author><surname>Badve</surname><given-names>S.</given-names></author><title>Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy</title><source>J. Pathol.</source><year>2006</year><volume>208</volume>
<author><surname>Friesen</surname><given-names>R. W.</given-names></author><author><surname>Mancini</surname><given-names>J. A.</given-names></author><title>Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target</title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume>
<author><surname>Thoren</surname><given-names>S.</given-names></author><author><surname>Jakobsson</surname><given-names>P. J.</given-names></author><title>Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4</title><source>Eur. J. Biochem.</source><year>2000</year><volume>267</volume>
<author><surname>Quraishi</surname><given-names>O.</given-names></author><author><surname>Mancini</surname><given-names>J. A.</given-names></author><author><surname>Riendeau</surname><given-names>D.</given-names></author><title>Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids</title><source>Biochem. Pharmacol.</source><year>2002</year><volume>63</volume>
<author><surname>Riendeau</surname><given-names>D.</given-names></author><author><surname>Aspiotis</surname><given-names>R.</given-names></author><author><surname>Ethier</surname><given-names>D.</given-names></author><author><surname>Gareau</surname><given-names>Y.</given-names></author><author><surname>Grimm</surname><given-names>E. L.</given-names></author><author><surname>Guay</surname><given-names>J.</given-names></author><author><surname>Guiral</surname><given-names>S.</given-names></author><author><surname>Juteau</surname><given-names>H.</given-names></author><author><surname>Mancini</surname><given-names>J. A.</given-names></author><author><surname>Methot</surname><given-names>N.</given-names></author><author><surname>Rubin</surname><given-names>J.</given-names></author><author><surname>Friesen</surname><given-names>R. W.</given-names></author><title>Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886</title><source>Bioorg. Med. Chem. Lett.</source><year>2005</year><volume>15</volume>
<author><surname>AbdulHameed</surname><given-names>M. D.</given-names></author><author><surname>Hamza</surname><given-names>A.</given-names></author><author><surname>Liu</surname><given-names>J.</given-names></author><author><surname>Huang</surname><given-names>X.</given-names></author><author><surname>Zhan</surname><given-names>C. G.</given-names></author><title>Human microsomal prostaglandin E synthase-1 (mPGES-1) binding with inhibitors and the quantitative structure&#8211;activity correlation</title><source>J. Chem. Inf. Model.</source><year>2008</year><volume>48</volume>
<author><surname>Cote</surname><given-names>B.</given-names></author><author><surname>Boulet</surname><given-names>L.</given-names></author><author><surname>Brideau</surname><given-names>C.</given-names></author><author><surname>Claveau</surname><given-names>D.</given-names></author><author><surname>Ethier</surname><given-names>D.</given-names></author><author><surname>Frenette</surname><given-names>R.</given-names></author><author><surname>Gagnon</surname><given-names>M.</given-names></author><author><surname>Giroux</surname><given-names>A.</given-names></author><author><surname>Guay</surname><given-names>J.</given-names></author><author><surname>Guiral</surname><given-names>S.</given-names></author><author><surname>Mancini</surname><given-names>J.</given-names></author><author><surname>Martins</surname><given-names>E.</given-names></author><author><surname>Masse</surname><given-names>F.</given-names></author><author><surname>Methot</surname><given-names>N.</given-names></author><author><surname>Riendeau</surname><given-names>D.</given-names></author><author><surname>Rubin</surname><given-names>J.</given-names></author><author><surname>Xu</surname><given-names>D.</given-names></author><author><surname>Yu</surname><given-names>H.</given-names></author><author><surname>Ducharme</surname><given-names>Y.</given-names></author><author><surname>Friesen</surname><given-names>R. W.</given-names></author><title>Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors</title><source>Bioorg. Med. Chem. Lett.</source><year>2007</year><volume>17</volume>
<author><surname>Claveau</surname><given-names>D.</given-names></author><author><surname>Sirinyan</surname><given-names>M.</given-names></author><author><surname>Guay</surname><given-names>J.</given-names></author><author><surname>Gordon</surname><given-names>R.</given-names></author><author><surname>Chan</surname><given-names>C. C.</given-names></author><author><surname>Bureau</surname><given-names>Y.</given-names></author><author><surname>Riendeau</surname><given-names>D.</given-names></author><author><surname>Mancini</surname><given-names>J. A.</given-names></author><title>Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model</title><source>J. Immunol.</source><year>2003</year><volume>170</volume>
<author><surname>San Juan</surname><given-names>A. A.</given-names></author><author><surname>Cho</surname><given-names>S. J.</given-names></author><title>3D-QSAR study of microsomal prostaglandin E2 synthase (mPGES-1) inhibitors</title><source>J. Mol. Model.</source><year>2007</year><volume>13</volume>
<author><surname>Jakobsson</surname><given-names>P. J.</given-names></author><author><surname>Morgenstern</surname><given-names>R.</given-names></author><author><surname>Mancini</surname><given-names>J.</given-names></author><author><surname>Ford-Hutchinson</surname><given-names>A.</given-names></author><author><surname>Persson</surname><given-names>B.</given-names></author><title>Common structural features of MAPEG&#8212;a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism</title><source>Protein Sci.</source><year>1999</year><volume>8</volume>
<author><surname>Jegerschold</surname><given-names>C.</given-names></author><author><surname>Pawelzik</surname><given-names>S. C.</given-names></author><author><surname>Purhonen</surname><given-names>P.</given-names></author><author><surname>Bhakat</surname><given-names>P.</given-names></author><author><surname>Gheorghe</surname><given-names>K. R.</given-names></author><author><surname>Gyobu</surname><given-names>N.</given-names></author><author><surname>Mitsuoka</surname><given-names>K.</given-names></author><author><surname>Morgenstern</surname><given-names>R.</given-names></author><author><surname>Jakobsson</surname><given-names>P. J.</given-names></author><author><surname>Hebert</surname><given-names>H.</given-names></author><title>Structural basis for induced formation of the inflammatory mediator prostaglandin E2</title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2008</year><volume>105</volume>
<author><surname>Rorsch</surname><given-names>F.</given-names></author><author><surname>Wobst</surname><given-names>I.</given-names></author><author><surname>Zettl</surname><given-names>H.</given-names></author><author><surname>Schubert-Zsilavecz</surname><given-names>M.</given-names></author><author><surname>Grosch</surname><given-names>S.</given-names></author><author><surname>Geisslinger</surname><given-names>G.</given-names></author><author><surname>Schneider</surname><given-names>G.</given-names></author><author><surname>Proschak</surname><given-names>E.</given-names></author><title>Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol</title><source>J. Med. Chem.</source><year>2010</year><volume>53</volume>
<author><surname>Koeberle</surname><given-names>A.</given-names></author><author><surname>Zettl</surname><given-names>H.</given-names></author><author><surname>Greiner</surname><given-names>C.</given-names></author><author><surname>Wurglics</surname><given-names>M.</given-names></author><author><surname>Schubert-Zsilavecz</surname><given-names>M.</given-names></author><author><surname>Werz</surname><given-names>O.</given-names></author><title>Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase</title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume>
<author><surname>Hessler</surname><given-names>G.</given-names></author><author><surname>Baringhaus</surname><given-names>K.-H.</given-names></author><title>The scaffold hopping potential of pharmacophores</title><source>Drug Discovery Today: Technol.</source><year>2010</year><volume>7</volume>
<author><surname>K&#246;berle</surname><given-names>A.</given-names></author><author><surname>Zettl</surname><given-names>H.</given-names></author><author><surname>Greiner</surname><given-names>C.</given-names></author><author><surname>Wurglics</surname><given-names>M.</given-names></author><author><surname>Schubert-Zsilavecz</surname><given-names>M.</given-names></author><author><surname>Werz</surname><given-names>O.</given-names></author><title>Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase</title><source>J. Med. Chem.</source><year>2008</year><volume>51</volume>
<person-group /><patent>Int. Pat. Appl. PCT WO 2005/123673 A1</patent><other>29</other><other>Dec</other><year>2005</year>
<person-group /><patent>Int. Pat. Appl. PCT WO 2005/123675 A1</patent><other>29</other><other>Dec</other><year>2005</year>
<author><surname>Edwards</surname><given-names>B. S.</given-names></author><author><surname>Bologa</surname><given-names>C.</given-names></author><author><surname>Young</surname><given-names>S. M.</given-names></author><author><surname>Balakin</surname><given-names>K. V.</given-names></author><author><surname>Prossnitz</surname><given-names>E. R.</given-names></author><author><surname>Savchuck</surname><given-names>N. P.</given-names></author><author><surname>Sklar</surname><given-names>L. A.</given-names></author><author><surname>Oprea</surname><given-names>T. I.</given-names></author><title>Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists</title><source>Mol. Pharmacol.</source><year>2005</year><volume>68</volume>
<author><surname>Rohrer</surname><given-names>S. G.</given-names></author><author><surname>Baumann</surname><given-names>K.</given-names></author><title>Maximum unbiased validation (MUV) data sets for virtual screening based on PubChem bioactivity data</title><source>J. Chem. Inf. Model.</source><year>2009</year><volume>49</volume>
<author><surname>Chen</surname><given-names>C. Y.-C.</given-names></author><title>Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping</title><source>J. Taiwan Inst. Chem. Eng.</source><year>2009</year><volume>40</volume>
<author><surname>Celotti</surname><given-names>F.</given-names></author><author><surname>Laufer</surname><given-names>S.</given-names></author><title>Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept</title><source>Pharmacol. Res.</source><year>2001</year><volume>43</volume>
<author><surname>Koeberle</surname><given-names>A.</given-names></author><author><surname>Siemoneit</surname><given-names>U.</given-names></author><author><surname>Buhring</surname><given-names>U.</given-names></author><author><surname>Northoff</surname><given-names>H.</given-names></author><author><surname>Laufer</surname><given-names>S.</given-names></author><author><surname>Albrecht</surname><given-names>W.</given-names></author><author><surname>Werz</surname><given-names>O.</given-names></author><title>Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1</title><source>J. Pharmacol. Exp. Ther.</source><year>2008</year><volume>326</volume>
<author><surname>Peters-Golden</surname><given-names>M.</given-names></author><author><surname>Henderson</surname><given-names>W. R.</given-names><suffix>Jr.</suffix></author><title>Leukotrienes</title><source>N. Engl. J. Med.</source><year>2007</year><volume>357</volume>
<author><surname>Hopkins</surname><given-names>A. L.</given-names></author><title>Network pharmacology: the next paradigm in drug discovery</title><source>Nature Chem. Biol.</source><year>2008</year><volume>4</volume>
<author><surname>Fischer</surname><given-names>L.</given-names></author><author><surname>Szellas</surname><given-names>D.</given-names></author><author><surname>Radmark</surname><given-names>O.</given-names></author><author><surname>Steinhilber</surname><given-names>D.</given-names></author><author><surname>Werz</surname><given-names>O.</given-names></author><title>Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors</title><source>FASEB J.</source><year>2003</year><volume>17</volume>
<author><surname>Werz</surname><given-names>O.</given-names></author><author><surname>Burkert</surname><given-names>E.</given-names></author><author><surname>Samuelsson</surname><given-names>B.</given-names></author><author><surname>Radmark</surname><given-names>O.</given-names></author><author><surname>Steinhilber</surname><given-names>D.</given-names></author><title>Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes</title><source>Blood</source><year>2002</year><volume>99</volume>